MYQORZO (aficamten) launched in major markets for oHCM
MYQORZO (aficamten) has launched in major markets for oHCM. The company says the launch is supported by clinical data and rapid commercial uptake, alongside pipeline and late-stage development for global expansion.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.